M&A activity related to orphan designated drugs decreased in the pharmaceutical industry in 2023

In value terms, orphan designated drugs-related deal activity increased by 58% in Q1 2023 compared with the previous quarter’s total of $31.8bn and rose by 1506% as compared to Q1 2022. Related deal volume decreased by 23% in Q1 2023 versus the previous quarter and was 5% higher than in Q1 2022.

The top-ranked financial advisors supporting these M&A deals in Q1 2023 were Centerview Partners; Bank of America; FTI Consulting with 4, 1, 1 deals respectively.

The top-ranked legal advisors supporting these M&A deals in Q1 2023 were Cooley; Fried, Frank, Harris, Shriver & Jacobson; Gibson, Dunn & Crutcher with 2, 2, 2 deals respectively.

For further understanding of GlobalData’s New Drug Approvals and Their Contract Manufacture – 2023 Edition buy the report here.

Subscribe to our Newsletter

Get industry leading news, data and analysis delivered to your inbox

Subscribe

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.